Skip to content

The research on blood dryness syndrome psoriasis microvessel regression mechanism influenced by Yangxuejiedu formula via Survivin-PI3K-ßcatenin signaling

The research on blood dryness syndrome psoriasis microvessel regression mechanism influenced by Yangxuejiedu formula via Survivin-PI3K-ßcatenin signaling

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016232
Enrollment
Unknown
Registered
2018-05-21
Start date
2018-05-21
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Case series:Yangxuejiedu formula orally and white vaseline externally

Sponsors

Beijing Hospital of TCM Affiliated Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Diagnostic criteria for psoriasis vulgaris; (2) Conforming to the syndrome differentiation standard of TCM syndrome differentiation; (3) Aged between 18 and 65 years.

Exclusion criteria

Exclusion criteria: (1) Joint type, pustular type, erythrodermic psoriasis; (2) Pregnant or lactating women; (3) In recent month internal and glucocorticoid and/or immunosuppressive drugs, and retinoic acid drugs, or two weeks, both inside and outside with glucocorticoid agents, drugs such as retinoic acid and vitamin D3 derivative preparation; (4) Patients with severe primary diseases and fine diseases including cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; (5) Allergy to the study drug.

Design outcomes

Primary

MeasureTime frame
survivin pro;

Countries

China

Contacts

Public ContactZhang Guangzhong

Beijing University of Traditional Chinese Medicine

zhgzh62000@126.com+86 15901132668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026